Vitamin D Signaling in Myogenesis: Potential for Treatment of Sarcopenia
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Muscle mass and strength progressively decrease with age, which results in a condition known as sarcopenia. Sarcopenia would lead to physical disability, poor quality of life, and death. Therefore, much is expected of an effective intervention for sarcopenia. Epidemiologic, clinical, and laboratory evidence suggest an effect of vitamin D on muscle function. However, the precise molecular and cellular mechanisms remain to be elucidated. Recent studies suggest that vitamin D receptor (VDR) might be expressed in muscle fibers and vitamin D signaling via VDR plays a role in the regulation of myoblast proliferation and differentiation. Understanding how vitamin D signaling contributes to myogenesis will provide a valuable insight into an effective nutritional strategy to moderate sarcopenia. Here we will summarize the current knowledge about the effect of vitamin D on skeletal muscle and myogenic cells and discuss the potential for treatment of sarcopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004
Janssen, I., Heymsfield, S. B., & Ross, R. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50216.x · Cited by 3,139
Goodpaster, B. H., Park, S. W., Harris, T. B., Kritchevsky, S. B., Nevitt, M., Schwartz, A. V., Simonsick, E. M., Tylavsky, F. A., Visser, M., Newman, A. B., et al. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.10.1059 · Cited by 3,083 · cited 1×
“Therefore, some studies [4, 5] suggest a working definition of sarcopenia: sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of”
BackgroundSarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399 · cited 1×
“Rosenberg from the Greek words sarx (meaning flesh) and penia (meaning loss) [1, 2].”
BackgroundLauretani, F., Russo, C. R., Bandinelli, S., Bartali, B., Cavazzini, C., Di Iorio, A., Corsi, A. M., Rantanen, T., Guralnik, J. M., & Ferrucci, L. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00246.2003 · Cited by 1,946
The healthcare costs of sarcopenia in the United States
Janssen, I., Shepard, D. S., Katzmarzyk, P. T., & Roubenoff, R. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52014.x · Cited by 1,546
Nongenomic actions of steroid hormones
Lösel, R., & Wehling, M. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1009 · Cited by 980 · cited 1×
“A nongenomic response to 1α,25(OH) 2 D 3 is characterized by a rapid (the seconds to minutes range) activation of signaling cascades and an insensitivity to inhibitors of transcription and protein synthesis [34].”
BackgroundAn overview of sarcopenia: facts and numbers on prevalence and clinical impact
von Haehling, S., Morley, J. E., & Anker, S. D. (2010) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-010-0014-2 · Cited by 888 · cited 1×
“Based on large-scale studies [12–16], on average, it is estimated that the prevalence of sarcopenia reaches 5–13% in those aged 60–70 years and ranges from 11 to 50% in those aged over 80 years [17].”
BackgroundDelmonico, M. J., Harris, T. B., Lee, J., Visser, M., Nevitt, M., Kritchevsky, S. B., Tylavsky, F. A., Newman, A. B., & for the Health, A. A. B. C. S. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01140.x · Cited by 819 · cited 1×
“Therefore, some studies [4, 5] suggest a working definition of sarcopenia: sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of”
Background
Cited by
Vitamin D Deficiency and Sarcopenia in Older Persons
Remelli, F., Vitali, A., Zurlo, A., & Volpato, S. (2019) · Nutrients · doi:10.3390/nu11122861 · Cited by 348
Cachexia and sarcopenia: mechanisms and potential targets for intervention
Argilés, J. M., Busquets, S., Stemmler, B., & López-Soriano, F. J. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.04.003 · Cited by 324
Sarcopenia in cirrhosis: from pathogenesis to interventions
Ebadi, M., Bhanji, R. A., Mazurak, V. C., & Montano-Loza, A. J. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01605-6 · Cited by 292
Mechanisms of vitamin D action in skeletal muscle
Montenegro, K. R., Cruzat, V., Carlessi, R., & Newsholme, P. (2019) · Nutrition Research Reviews · doi:10.1017/s0954422419000064 · Cited by 147
Vitamin D, Muscle Recovery, Sarcopenia, Cachexia, and Muscle Atrophy
Garcia, M., Seelaender, M., Sotiropoulos, A., Coletti, D., & Lancha, A. H. (2019) · Nutrition · doi:10.1016/j.nut.2018.09.031 · Cited by 105
Metadata
- Authors
- Wagatsuma, A., & Sakuma, K.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-13
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2085184858
- Cited by
- 71
- References
- 30
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vitamin D Signaling in Myogenesis: Potential for Treatment of Sarcopenia. https://app.cochat.ai/papers/10.1155/2014/121254
- The paper
- Wagatsuma, A., & Sakuma, K. (2014). Vitamin D Signaling in Myogenesis: Potential for Treatment of Sarcopenia. BioMed Research International. https://doi.org/10.1155/2014/121254
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.